Hurum Co (353190) Fair Value & Analysis
Consumer Defensive · KR · Market cap 23.7B KRW
Fair value as of: Jun 24, 2026
Analysis
Hurum Co (353190) currently trades at 2,925 KRW, while our model-based Fair Value estimate is 2,506 KRW — implying the stock looks roughly 14.3% overvalued today. We read business quality at 90/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Hurum Co., Ltd. researches, develops, manufactures, and distributes health supplements in South Korea and internationally. The company offers lactobacillus under the TrueLAC brand name; yogurt, yogurt maker, and seed probiotics under the Yogurberry brand; mandarin oranges under the Jeju Orange Factory brand name; raw materials and ingredients for cafes under the I'mYo brand; and health functional foods under the V:nergy brand name. It also operates frozen yogurt franchise store under the Yogurberry name. In addition, the company offers various health supplements Joint Smile, Lutein Zeaxanthin, Real Sleep, Empress's Pu'er Tea Diet, Cissus Speed Diet, and Estriple brand names. Further, it distributes products through various channels, such as large distribution, retailers, resorts, cafes, and online. The company was founded in 2005 and is headquartered in Seoul, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Hurum Co (353190) undervalued?
What is the fair value of 353190?
What is the quality score of 353190?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.